Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMD006 in Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors
NCT06928922Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMD006 in lung cancer and solid tumor (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicities at 2 years, Maximum Tolerated Dose at 2 years and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
BMD006
03
Conditions
lung cancersolid tumor
Beyond the preview
Go deeper on NCT06928922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928922.